Micregen's Secretomix® platform was selected as a finalist for the 2023 UK Pharma Industry Awards, Innovation of the Year.

The Pharma Industry Awards identify and celebrate outstanding individuals and companies within the UK pharma industry who showcase excellence and originality. The Innovation of the Year is reserved for a unique product, process, or technology that yielded significant results and delivered to the highest standard.

This recognition demonstrates the far-reaching potential of Micregen's Secretomix® platform and the significant benefits it could bring to humanity.

Micregen completed the development of a suite of In-Process-Control, Potency and Release Assays to manufacture clinical grade Secretomix®.

Pre-clinical research continued throughout 2022 in the UK, USA, and Canada in CRO, university and hospital laboratories.

Micregen’s new commercial office opened at Alderley Park, Cheshire.

Micregen was listed amongst the UK’s top 200 most valuable high-growth companies in a joint report produced by Singer Capital Markets, a leading investment bank, and Beauhurst, a trusted searchable database of the UK’s high-growth companies.

From the 4.2 million private UK companies, over 34,000 met Beauhurst’s high-growth criteria, nearly 12,000 of which had received qualifying investment over the three-year period covered by the report. Micregen was proud to be placed at 192.

Micregen initiated the 2021 funding round led by Pitalia Private Family Office.

Further financial support from Micregen shareholders with new equity investment as Micregen entered an exciting phase of development.

Micregen appointed pharma business development expert Joanne Kelley as Business Development Director. Jo is a senior biopharmaceutical business development leader with extensive global commercial and general management experience and an outstanding record of strategy development, deal preparation and execution. Her last role at AstraZeneca was VP Business Development - Head of Transactions.

Jo has diverse experience in leading buy and sell life sciences deals, including M&A, licensing, collaboration, and divestments. Her track record includes leading transformational, high-value transactions at AstraZeneca.

Micregen welcomed its stakeholders to Alderley Park for the annual investor meeting.

Micregen won a £395k Smart Award under the UK Government’s modern industrial strategy from Innovate UK, part of UK Research and Innovation (UKRI).

Micregen welcomed its stakeholders to Alderley Park for the annual investor meeting.

Peter Ormerod was appointed as Non-Exec Director. Peter built his family business to an exit with over 400 shops nationwide, which was recognised as the largest Hearing Aid and Audiology provider in the UK.

Peter was also instrumental in the successful sale of the business to the Swiss Sonova Group and the subsequent part sale of the business to Boots the Chemist, including overseeing the rebrand to Boots Hearingcare, which he went on to chair.

Cary Depel was appointed to the Micregen Board. A qualified USA Lawyer & UK Solicitor with an accounting, finance and risk management background, Cary has held positions of Compliance Director and Chief Risk Officer in the UK and USA across several sectors, including biotech and medical device manufacturing. He is a former Fellow and Chairman of the Institute of Risk Management.

The scientific team was assembled, including:

Prof. Paolo De Coppi, Professor of Paediatric Surgery at University College London & Great Ormond Street Hospital. Divisional Head at The Institute for Child Health.​

Prof. Ketan Patel, Professor of Regenerative Medicine & Head of Molecular and Cellular Medicine University of Reading, Adjunct Professor at Eppendorf University Clinic, Germany.

Dr Robert Mitchell. Studying under Professor Patel, Rob obtained his PhD at the University of Reading with his thesis exploring the regenerative capabilities of adult stem cell secretomes.